Enifer Advances PEKILO Mycoprotein Toward U.S. Market with FDA GRAS Submission
Enifer has submitted a notified GRAS dossier to the U.S. Food and Drug Administration for its PEKILO mycoprotein, moving the ingredient into formal regulatory review and positioning the company for large-scale partnerships in the U.S. food sector.
The submission follows Enifer’s self-affirmed GRAS determination in 2025 and represents a key step in securing a “no questions” letter from the FDA – widely seen as essential for adoption by major food manufacturers operating under strict compliance frameworks.
Targeting industrial-scale food applications
PEKILO is a fermentation-derived protein and fibre ingredient produced from food and agricultural side streams using proprietary technology developed in Finland. The shelf-stable powder contains up to 50% protein and 35% fibre, with a neutral taste and colour designed for broad application across categories including snacks, bakery, dairy and meat alternatives, and hybrid products.
Its “drop-in” functionality allows manufacturers to boost protein and fibre content without impacting sensory profiles, aligning with growing demand for clean-label, functional ingredients that can integrate into existing production systems.
Regulatory clarity drives adoption
The move comes as global protein ingredient markets continue to expand, with manufacturers increasingly prioritising regulatory certainty and supply chain resilience when evaluating new inputs. In the U.S., alternative protein ingredients are expected to see sustained double-digit growth, driven by reformulation strategies and evolving consumer demand.
Elisa Arte, Head of Food R&D at Enifer, said FDA-notified GRAS status is critical for progressing from product trials to long-term supply agreements, particularly as manufacturers focus on scalability and cost efficiency.
Scaling production alongside market entry
Alongside regulatory progress, Enifer is ramping up production capacity in Finland ahead of a planned scale-up in 2026. The company aims to align manufacturing readiness with regulatory approval to support structured, long-term supply partnerships in the U.S. market.
CEO and co-founder Simo Ellilä said the company is responding to a shift in how manufacturers source protein, with increasing emphasis on performance, reliability and industrial scalability.
The FDA review process is expected to continue through 2026, as Enifer expands commercial discussions with U.S. food manufacturers across multiple application segments, including bakery and ready-to-eat products.